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The guest editors of this special issue, both members of the
European Association of Urology Guidelines Ofﬁce deal-
ing with male lower urinary tract symptoms and benign
prostatic hyperplasia (BPH), have been asked by the edi-
torial board of the World Journal of Urology to collect and
publish a series of articles on BPH to document the latest
developments of this disease. Next to this issue solely
dealing with the treatment of BPH, another special issue on
basic science, epidemiology, and assessment of BPH is
already in preparation and anticipated to be published later
in 2010. Both special issues contain a mixture of original
scientiﬁc as well as review articles on BPH and summarize
the latest knowledge of the BPH disease. We thank all
authors who have followed our invitation and shared their
professional inside information with us. As all articles have
been peer-reviewed, we would also like to thank all
reviewers for their valuable time, work, and suggestions.
BPH is the term used only to describe benign growth of
epithelial, muscular, and/or ﬁbrotic cells in the prostate.
Microscopic changes increase with ageing and approxi-
mately 40, 70, 80, and 90% of men are affected in their
sixth, seventh, eighth, and ninth decade, respectively [1].
Based on the prevalence data, BPH appears to be a
physiological ageing process. BPH becomes a disease
when benign prostatic enlargement (BPE), benign prostatic
obstruction (BPO), or lower urinary tract symptoms
(LUTS) appear. No strict correlations between these
components have been found so far and, therefore, each
component of the BPH disease has to be assessed and
treated separately. It is estimated that one-third to one-half
of men with BPH develop BPE, approximately half of men
with BPH–LUTS have BPO, and up to 40% of men in a
community have LUTS.
LUTS is the most frequent cause of annoyance and
decreased life quality in patients with BPH and associated
with health-seeking behavior [2]. Although in most cases
not life-threatening, BPH–LUTS has a tremendous socio-
economic impact. Data from the Integrated Health Care
Information Solutions National Managed Care Benchmark
Database which included more than 30 health care plans
between July 1997 and January 2003 and covered 25
million men aged 50 years or older demonstrated that
BPE–LUTS is the ﬁfth most commonly treated disease in
the US, following cataracts, hypertension, osteoarthritis,
and bursitis [3]. It was calculated from this database that
medical costs of BPE–LUTS are among the seven most
costly diseases. The chance of developing a signiﬁcant
clinical event (deﬁned as acute urinary retention or need for
prostate surgery) within 12 months after initiating medical
treatment was the second highest of all diseases. Inpatient
treatment of BPE–LUTS was responsible for 40% of the
total costs which were only higher for cataracts, coronary
artery diseases, osteoarthritis, and arrhythmias. It was
concluded that improvement of the understanding of BPE
(BPO or LUTS) would have the potential to signiﬁcantly
decrease costs. However, it is expected that the number of
patients will dramatically increase as the average life
expectancy increases worldwide, and therefore, further
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and LUTS will help in decreasing the cost related to BPH-
related conditions.
Assessment and treatment of BPH, BPE, BPO, or male
LUTS has been and will be the ‘‘bread and butter’’ of
urologists not only because of the pure amount of patients,
but also because of the special skills necessary to treat
these patients. Urology would deﬁnitely not exist as a
separate specialization without BPH and BPH-speciﬁc
treatments. Amazingly, the importance of this disease is
not reﬂected by the amount of publications in peer-
reviewed journals or abstracts of major urology congresses.
Of 536 published articles in European Urology in 2009,
only 12 articles (2.2%) dealt with BPH or male LUTS.
Therefore, the number one topic of urology is clearly
underrepresented in the current literature. The guest editors
of this issue of the World Journal of Urology are therefore
grateful to have the opportunity to draw more attention to
the most frequent urological disease. We wish our readers a
joyful and interesting time reading the following articles on
medical or surgical treatment of clinical BPH.
Yours,
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